InvestorsHub Logo
Post# of 253160
Next 10
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

Re: jq1234 post# 162348

Wednesday, 07/30/2014 12:32:17 PM

Wednesday, July 30, 2014 12:32:17 PM

Post# of 253160
AZN acquires respiratory portfolio and pipeline from Almirall:

http://online.wsj.com/articles/astrazeneca-to-buy-rights-to-almirall-respiratory-drugs-1406707162

AstraZeneca PLC has agreed to buy the rights to a portfolio of inhaled drugs from Almirall SA in a deal worth up to $2.1 billion, a significant step toward expanding its respiratory business and the type of pipeline-boosting deal favored by Chief Executive Pascal Soriot.

The deal will give the U.K. drug maker a type of treatment for chronic obstructive pulmonary disease which it currently lacks, a new type of inhaler and a portfolio of pipeline drugs, potentially helping it compete better with rivals such as respiratory-market leader GlaxoSmithKline

…However, the deal doubles up on a number of pipeline drugs that AstraZeneca acquired through its 2013 purchase of Pearl Therapeutics [#msg-88847837].

"We see a significant overlap with the recently acquired Pearl's assets, which could raise questions about AstraZeneca's strategy in respiratory," Morgan Stanley said in a research note.

AstraZeneca said it would pay the Spanish drug maker an initial consideration of $875 million and up to a further $1.22 billion in development, launch and sales-related milestones and payments. That values the portfolio around 2.6 times revenue, Panmure Gordon said in a note.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.